Bvf Inc Viridian Therapeutics, Inc.\De Transaction History

Bvf Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $26.8 Million - $40.3 Million	-1,070,974 Reduced 86.44%	168,000 $4.27 Million
Q4 2022 Feb 14, 2023	SELL	$18.78 - $29.74 $9.44 Million - $15 Million	-502,866 Reduced 28.87%	1,238,974 $36.2 Million
Q3 2022 Nov 14, 2022	SELL	$10.7 - $25.5 $23,240 - $55,386	-2,172 Reduced 0.12%	1,741,840 $35.7 Million
Q1 2022 May 16, 2022	SELL	$16.79 - $20.88 $2.27 Million - $2.83 Million	-135,400 Reduced 7.2%	1,744,012 $32.2 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $16.8 Million - $23.1 Million	1,075,286 Added 133.72%	1,879,412 $37.2 Million
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $4.85 Million - $8.26 Million	454,045 Added 129.7%	804,126 $13.2 Million
Q2 2021 Aug 16, 2021	SELL	$14.34 - $18.67 $1.63 Million - $2.12 Million	-113,423 Reduced 24.47%	350,081 $6.4 Million
Q1 2021 May 17, 2021	BUY	$15.5 - $24.93 $7.18 Million - $11.6 Million	463,504 New	463,504 $7.75 Million

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $806M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.